Everolimus plus R-CHOP-21 is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG N1085 (Alliance)
- Citation:
- Blood vol 126 (23) abstr 813
- Meeting Instance:
- ASH 2015
- Year:
- 2015
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2456
- Pharmas:
- Grants:
- U10CA180821, UG1CA189823, U10CA180882
- Corr. Author:
- Authors:
- Patrick B. Johnston Betsy R. LaPlant Ellen D. McPhail Thomas M. Habermann David J. Inwards Ivana Micallef Joseph Colgan Grzegorz Nowakowski Stephen M. Ansell Thomas E. Witzig
- Networks:
- LAPS-MN026
- Study
- NCCTG-N1085
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1
- Keywords:
- non-Hodgkin lymphoma, mTORC1 inhibitor, everolimus